C-Jun N-terminal kinase inhibitors: A patent review (2010-2014)

Expert Opinion on Therapeutic Patents

Volumn 25, Issue 8, 2015, Pages 849-872

  Gehringer, Matthias ^a   Muth, Felix ^a   Koch, Pierre ^a   Laufer, Stefan A ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Alzheimer's disease; C Jun N terminal kinase inhibitors; Cancer; Cardiovascular disorders; Chemical probes; Dual leucine zipper kinase; Huntington's disease; Inflammation; Isoform selectivity; JNK1; JNK2; JNK3; MAPK kinases; Metabolic disorders; Mitogen activated protein kinase kinase 4; Neurodegenerative disorders; P38 MAP kinase; Parkinson's disease; Stroke

Indexed keywords

ISOENZYME; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN KINASE INHIBITOR;

ALLOSTERISM; COVALENT BOND; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG SELECTIVITY; HUMAN; IN VIVO STUDY; NONHUMAN; PATENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DESIGN; METABOLISM; MOLECULARLY TARGETED THERAPY;

ANIMALS; DRUG DESIGN; HUMANS; ISOENZYMES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR TARGETED THERAPY; PATENTS AS TOPIC; PROTEIN KINASE INHIBITORS;

EID: 84937208281     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2015.1039984     Document Type: Review

References (83)

1. Grant SK. Therapeutic Protein Kinase Inhibitors. Cell Mol Life Sci 2009;66(7):1163-77
2. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science (Washington, DC, U S) 2002;298(5600):1911-12
3. Cui J, Zhang M, Zhang Y-Q, et al. JNK pathway: diseases and therapeutic potential. Acta Pharmacol Sin 2007;28(5):601-8
4. Gupta S, Barret T, Whitmarsh AJ, et al. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J 1996;15(11):2760-70
5. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009;9(8):537-49
6. Whitmarsh AJ, Cavanagh J, Tournier C, et al. A mammalian scaffold complex that selectively mediates MAP kinase activation. Science (Washington, D C) 1998;281(5383):1671-4
7. Bogoyevitch MA, Kobe B. Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases. Microbiol Mol Biol Rev 2006;70(4):1061-95
8. Koch P, Gehringer M, Laufer SA. Inhibitors of c-jun N-terminal kinases: An update. J Med Chem 2015;58(1):72-95
9. Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome. Science (Washington, DC, U S) 2002;298(5600):1912-16; 33-34
10. Graczyk PP. JNK inhibitors as antiinflammatory and neuroprotective agents. Future Med Chem 2013;5(5):539-51
11. Perrin V, Dufour N, Raoul C, et al. Implication of the JNK pathway in a rat model of Huntington's disease. Exp Neurol 2009;215(1):191-200
12. Swantek JL, Cobb MH, Geppert TD. Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor a (TNF-a) translation: glucocorticoids inhibit TNF-a translation by blocking JNK/ SAPK. Mol Cell Biol 1997;17(11):6274-82
13. Guma M, Ronacher LM, Firestein GS, et al. JNK-1 deficiency limits macrophage-mediated antigen-induced arthritis. Arthritis Rheum 2011;63(6):1603-12
14. Vallerie SN, Hotamisligil GS. The role of JNK proteins in metabolism. Sci Transl Med 2010;2(60):60rv5
15. Bubici C, Papa S. JNK signalling in cancer: in need of new, smarter therapeutic targets. Br J Pharmacol 2014;171(1):24-37
16. Bennett BL, Sasaki DT, Murray BW, et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 2001;98(24):13681-6
17. Fabian MA, Biggs WH, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23(3):329-36
18. Siddiqui MA, Reddy PA. Small molecule JNK (c-Jun N-terminal kinase) inhibitors. J Med Chem 2010;53(8):3005-12
19. Stebbins JL, De SK, Pavlickova P, et al. Design and characterization of a potent and selective dual ATP-and substratecompetitive subnanomolar bidentate c-Jun N-terminal kinase (JNK) inhibitor. J Med Chem 2011;54(18):6206-14
20. Zhang T, Inesta-Vaquera F, Niepel M, et al. Discovery of potent and selective covalent inhibitors of JNK. Chem Biol (Oxford, U K) 2012;19(1):140-54
21. Krenitsky VP, Delgado M, Nadolny L, et al. Aminopurine based JNK inhibitors for the prevention of ischemia reperfusion injury. Bioorg Med Chem Lett 2012;22(3):1427-32
22. Haynes N-E, Scott NR, Chen LC, et al. Identification of an adamantyl azaquinolone JNK selective inhibitor. ACS Med Chem Lett 2012;3(9):764-8
23. Gaillard P, Jeanclaude-Etter I, Ardissone V, et al. Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase. J Med Chem 2005;48(14):4596-607
24. PGL5001 Proof of Concept Study in Inflammatory Endometriosis-Full Text View-ClinicalTrials. gov. Available from: https://clinicaltrials. gov/ct2/show/ NCT01630252 term=NCT01630252&rank=1 [Accessed 14 January 2015]
25. Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss-Full Text View-ClinicalTrials. gov. Available from: https://clinicaltrials. gov/ct2/show/ NCT00802425 [Accessed 12 January 2015]
26. Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation-Full Text View-ClinicalTrials. gov. Available from: https://clinicaltrials. gov/ct2/show/ NCT02235272 [Accessed 12 January 2015]
27. Bogoyevitch MA, Ngoei KRW, Zhao TT, et al. c-Jun N-terminal kinase (JNK) signaling: recent advances and challenges. Biochim Biophys Acta 2010;1804(3):463-75
28. Arzeno HB, Filonova L, Goldstein DM, et al. Preparation of 2-aminopyrimidine derivatives as JNK inhibitors. WO2011151358A1; 2011
29. Buettelmann B, Goyal B, Palmer WS. Preparation of cyclohexylamino pyrimidinylimidazopyridine derivatives for use as JNK modulators. WO2010097335A1; 2010
30. Gong L, Han X, Makra F, et al. Pyrimidine derivatives as JNK inhibitors and their preparation and use for the treatment of JNK-mediated diseases. US20110034470A1; 2011
31. Gong L, Jahangir A, Reuter DC. Pyrimidin-2-ylamine derivatives as JNK inhibitors and their preparation and use for the treatment of inflammation. WO2010069833A1; 2010
32. Gong L, Tan Y-C. Preparation of 2-aminopyrimidine derivatives as JNK inhibitors. WO2011151357A1; 2011
33. Palmer WS, Alam M, Arzeno HB, et al. Development of amino-pyrimidine inhibitors of c-Jun N-terminal kinase (JNK): Kinase profiling guided optimization of a 1, 2, 3-benzotriazole lead. Bioorg Med Chem Lett 2013;23(5):1486-92
34. Goldstein DM, Gong L, Michoud C, et al. Preparation of aminopyrimidinylbenzotriazoles as kinase modulators. WO2008028860A1; 2008
35. Gong L, Han X, Silva T, et al. Development of indole/indazoleaminopyrimidines as inhibitors of c-Jun N-terminal kinase (JNK): Optimization for JNK potency and physicochemical properties. Bioorg Med Chem Lett 2013;23(12):3565-9
36. Boice GN, Gong L, McCaleb KL, et al. Pyrimidinyl pyridone derivatives as inhibitors of JNK, their preparation and use for treatment of diseases associated with excessive JNK activity. WO2010046273A2; 2010
37. Cheung AW-H, Guertin KR, Haynes N-E, et al. Preparation of adamantane derivatives for treatment of JNKs-mediated disorders. WO2012136684A1; 2012
38. Gong L, Tan Y-C, Boice G, et al. Discovery of a novel series of 4-quinolone JNK inhibitors. Bioorg Med Chem Lett 2012;22(24):7381-7
39. Bilotta JA, Cheung AW-H, Firooznia F, et al. Aminomethylquinolone compounds as JNK inhibitors and their preparation. WO2013007676A1; 2013
40. Beauchamps MG, Harris LM, Kothare MA, et al. Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2, 4, 6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol for treatment of cancer, inflammation and autoimmune diseases. WO2011071491A1; 2011
41. A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus-Full Text View-ClinicalTrials. gov. Available from: https://clinicaltrials. gov/ct2/show/ NCT01466725 [Accessed 10 January 2015]
42. A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)-Full Text View-ClinicalTrials. gov. Available from: https://clinicaltrials. gov/ ct2/show/NCT01203943 [Accessed 10 January 2015]
43. Albers R, Ayala L, Clareen S, et al. Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith. Google Patents; 2007
44. Albers R, Ayala L, Clareen SS, et al. Preparation of haloaryl substituted aminopurines for use as a prodrug in the treatment of cancers, cardiovascular or renal diseases. WO2006076595A1; 2006
45. Plantevin Krenitsky V, Nadolny L, Delgado M, et al. Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor. Bioorg Med Chem Lett 2012;22(3):1433-8
46. Bennett BL, Elsner J, Erdman P, et al. Preparation of substituted diaminocarboxamide and diaminocarbonitrile pyrimidines as JNK pathway inhibitors. WO2012145569A1; 2012
47. Graczyk P, Khan A, Bhatia G, et al. Preparation of pyrrolo[2, 3-b]pyrimidines as inhibitors of c-Jun N-terminal kinases (JNKs) inhibitors for the treatment of neurodegenerative disorders. WO2004078756A2; 2004
48. Graczyk PP, Dimopoulos P, Khan A, et al. 7-Azaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase and their preparation. WO2008095944A1; 2008
49. Graczyk P, Bhatia GS. Diazaindole derivatives, their preparation and therapeutic use as inhibitors of c-Jun N-terminal kinase. WO2010015803A1; 2010
50. Gehringer M, Forster M, Pfaffenrot E, et al. Novel hinge-binding motifs for janus kinase 3 inhibitors: A comprehensive structure-activity relationship study on tofacitinib bioisosteres. ChemMedChem 2014;9(11):2516-27
51. Gray N, Zhang T. Preparation of pyrimidineamine compounds as inhibitors of c-Jun-N-terminal kinase (JNK). WO2013074986A1; 2013
52. Knapp S, Arruda P, Blagg J, et al. A public-private partnership to unlock the untargeted kinome. Nat Chem Biol 2013;9(1):3-6
53. Kamenecka T, Jiang R, Song X, et al. Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal Kinase (JNK) inhibitors. J Med Chem 2010;53(1):419-31
54. Javaherian A. Screening methods for identifying agents that modulate DNAbinding proteins TDP-43 and therapeutic uses thereof in the treatment of TDP-43 proteinopathies. WO2013169793A2; 2013
55. Huang L, Liu S, Lunney EA, et al. Substituted 2-amino-fused heterocyclic compounds as JNK modulators and their preparation, pharmaceutical compositions and use in the treatment of diabetes and related diseases. WO2007125405A2; 2007
56. Pellecchia M. Bi-dentate compounds as kinase inhibitors. WO2012083092A2; 2012
57. Heo Y-S, Kim S-K, Seo CI, et al. Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125. EMBO J 2004;23(11):2185-95
58. Yang X, Hadida Ruah SS, Grootenhuis PDJ, et al. Preparation of phenyloxodihydroquinolinecarboxamide derivatives for use as cystic fibrosis transmembrane conductance regulator modulators. WO2010108155A1; 2010
59. De SK, Barile E, Chen V, et al. Design, synthesis, and structure-activity relationship studies of thiophene-3-carboxamide derivatives as dual inhibitors of the c-Jun N-terminal kinase. Bioorg Med Chem 2011;19(8):2582-8
60. Bonny C. Cell-permeable peptide inhibitors of the JNK signal transduction pathway and their therapeutic use. WO2001027268A2; 2001
61. Bonny C. Cell-permeable peptide inhibitors of JNK (c-Jun amino terminal kinase) signal transduction pathway and their therapeutic use. WO2007031280A2; 2007
62. Bonny C. Novel (poly-)peptide JNK inhibitor molecules. WO2011160653A1; 2011
63. Bonny C, Oberson A, Negri S, et al. Cell-permeable peptide inhibitors of JNK: novel blockers of b-cell death. Diabetes 2001;50(1):77-82
64. Combette J-M, Deloche C, Abadie C. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of inflammatory eye disease. WO2012048721A1; 2012
65. Combette J-M, Deloche C. Use of cellpermeable peptide inhibitors of the JNK signal transduction pathway for the treatment of dry eye syndrome. WO2013079213A1; 2013
66. Kaoud TS, Mitra S, Lee S, et al. Development of JNK2-selective peptide inhibitors that inhibit breast cancer cell migration. ACS Chem Biol 2011;6(6):658-66
67. Combette J-M, Deloche C. Novel JNK inhibitory (poly-)peptides for treatment of various diseases. WO2013091670A1; 2013
68. Efficacy and Safety of XG-104 for the Treatment of Dry Eye-Full Text View-ClinicalTrials. gov. Available from: https://clinicaltrials. gov/ct2/show/ NCT02235259term=xg-104&rank=1 [Accessed 13 January 2015]
69. Sham HL, Konradi AW, Hom RK, et al. Preparation of N-(thiophen-3-yl) acetamide derivatives as inhibitors of JNK N-terminal kinase. WO2010091310A1; 2010
70. Hom RK, Bowers S, Sealy JM, et al. Design and synthesis of disubstituted thiophene and thiazole based inhibitors of JNK. Bioorg Med Chem Lett 2010;20(24):7303-7
71. Bowers S, Truong AP, Neitz RJ, et al. Design and synthesis of a novel, orally active, brain penetrant, TRI-substituted thiophene based JNK inhibitor. Bioorg Med Chem Lett 2011;21(6):1838-43
72. Bowers S, Truong AP, Jeffrey Neitz R, et al. Design and synthesis of brain penetrant selective JNK inhibitors with improved pharmacokinetic properties for the prevention of neurodegeneration. Bioorg Med Chem Lett 2011;21(18):5521-7
73. Zimmermann MO, Lange A, Wilcken R, et al. Halogen-enriched fragment libraries as chemical probes for harnessing halogen bonding in fragment-based lead discovery. Future Med Chem 2014;6(6):617-39
74. Cellamare S, Carotti A, Stefanachi A, et al. Galloyl benzamide-based compounds as JNK modulators. WO2014170706A1; 2014
75. Pellicani RZ, Stefanachi A, Niso M, et al. Potent galloyl-based selective modulators targeting multidrug resistance associated protein 1 and P-glycoprotein. J Med Chem 2012;55(1):424-36
76. Singh J, Petter RC, Baillie TA, et al. The resurgence of covalent drugs. Nat Rev Drug Discov 2011;10(4):307-17
77. Serafimova IM, Pufall MA, Krishnan S, et al. Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles. Nat Chem Biol 2012;8(5):471-6
78. Backes AC, Zech B, Felber B, et al. Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition. Expert Opin Drug Discov 2008;3(12):1427-49
79. Kuglstatter A, Ghate M, Tsing S, et al. X-ray crystal structure of JNK2 complexed with the p38a inhibitor BIRB 796: Insights into the rational design of DFG-out binding MAP kinase inhibitors. Bioorg Med Chem Lett 2010;20(17):5217-20
80. Taylor SS, Kornev AP. Protein kinases: evolution of dynamic regulatory proteins. Trends Biochem Sci 2011;36(2):65-77
81. Taylor DM, Moser R, Regulier E, et al. MAP kinase phosphatase 1 (MKP-1/ DUSP1) is neuroprotective in Huntington's disease via additive effects of JNK and p38 inhibition. J Neurosci 2013;33(6):2313-25
82. Muth F, Günther M, Bauer SM, et al. Tetra-substituted pyridinylimidazoles as dual inhibitors of p38a mitogenactivated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases. J Med Chem 2015;58(1):443-56
83. Tedeschi A, Bradke F. The DLK signalling pathway-a double-edged sword in neural development and regeneration. EMBO Rep 2013;14(7):605-14